CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN

The article describes international multicenter controlled studies of efficacy and safety of monoclonal antibodies towards interleukin 1β — kanakinumab — when treating cryopyrin-associated periodic syndrome and systemic juvenile idiopathic arthritis in children. The results of the studies show that...

Full description

Bibliographic Details
Main Authors: Ye. I. Alekseeva, R. V. Denisova
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2014-12-01
Series:Вопросы современной педиатрии
Subjects:
Online Access:https://vsp.spr-journal.ru/jour/article/view/95
_version_ 1797700425819881472
author Ye. I. Alekseeva
R. V. Denisova
author_facet Ye. I. Alekseeva
R. V. Denisova
author_sort Ye. I. Alekseeva
collection DOAJ
description The article describes international multicenter controlled studies of efficacy and safety of monoclonal antibodies towards interleukin 1β — kanakinumab — when treating cryopyrin-associated periodic syndrome and systemic juvenile idiopathic arthritis in children. The results of the studies show that the remission of the disease occurred in 90% of patients with cryopyrin-associated periodic syndrome and in 40% of patients with systemic juvenile idiopathic arthritis. The safety profile was comparable to that of other biological agents.
first_indexed 2024-03-12T04:21:44Z
format Article
id doaj.art-21ffc31d284c4ee4a672ad52e3c154b4
institution Directory Open Access Journal
issn 1682-5527
1682-5535
language English
last_indexed 2024-03-12T04:21:44Z
publishDate 2014-12-01
publisher "Paediatrician" Publishers LLC
record_format Article
series Вопросы современной педиатрии
spelling doaj.art-21ffc31d284c4ee4a672ad52e3c154b42023-09-03T10:32:54Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352014-12-0113691410.15690/vsp.v13i6.119595CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDRENYe. I. Alekseeva0R. V. Denisova1Научный центр здоровья детей, Москва;, Первый Московский государственный медицинский университет им. И.М. СеченоваНаучный центр здоровья детей, МоскваThe article describes international multicenter controlled studies of efficacy and safety of monoclonal antibodies towards interleukin 1β — kanakinumab — when treating cryopyrin-associated periodic syndrome and systemic juvenile idiopathic arthritis in children. The results of the studies show that the remission of the disease occurred in 90% of patients with cryopyrin-associated periodic syndrome and in 40% of patients with systemic juvenile idiopathic arthritis. The safety profile was comparable to that of other biological agents.https://vsp.spr-journal.ru/jour/article/view/95детиканакинумабсистемный ювенильный идиопатический артриткриопиринассоциированные периодические синдромы
spellingShingle Ye. I. Alekseeva
R. V. Denisova
CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
Вопросы современной педиатрии
дети
канакинумаб
системный ювенильный идиопатический артрит
криопиринассоциированные периодические синдромы
title CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
title_full CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
title_fullStr CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
title_full_unstemmed CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
title_short CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
title_sort canakinumab in the treatment of rheumatic diseases in children
topic дети
канакинумаб
системный ювенильный идиопатический артрит
криопиринассоциированные периодические синдромы
url https://vsp.spr-journal.ru/jour/article/view/95
work_keys_str_mv AT yeialekseeva canakinumabinthetreatmentofrheumaticdiseasesinchildren
AT rvdenisova canakinumabinthetreatmentofrheumaticdiseasesinchildren